Leucine-rich repeat-containing protein 19 suppresses colorectal cancer by targeting cyclin-dependent kinase 6/E2F1 and remodeling the immune microenvironment

Figure 4 Drug binding affinity to leucine-rich repeat-containing 19 drug and molecular docking. A: Amuvatinib binding affinity to leucine-rich repeat-containing 19 (LRRC19) drug and molecular docking; B: Ciclopirox binding affinity to LRRC19 drug and molecular docking; C: Docetaxel binding affinity to LRRC19 drug and molecular docking; D: Elesclomol binding affinity to LRRC19 drug and molecular docking; E: JNK Inhibitor VIII binding affinity to LRRC19 drug and molecular docking; F: Piperlongumine binding affinity to LRRC19 drug and molecular docking; G: Sepantronium bromide binding affinity to LRRC19 drug and molecular docking; H: STF-62247 binding affinity to LRRC19 drug and molecular docking.